Oxygenta Pharmaceutical (524636) Q1 24/25 earnings summary

Executive summary

• Un-audited financial results for the quarter ended June 30, 2024, were approved and reviewed by the Board and statutory auditors.

• The company operates in a single segment, with results reflecting this focus.

Financial highlights

• Revenue from operations for Q1 FY25 was ₹1,262.08 lakhs, up from ₹686.39 lakhs in Q1 FY24 and ₹1,055.24 lakhs in Q4 FY24.

• Total expenses for Q1 FY25 were ₹1,546.03 lakhs, compared to ₹1,129.37 lakhs in Q1 FY24 and ₹1,339.97 lakhs in Q4 FY24.

• Net loss for Q1 FY25 stood at ₹145.37 lakhs, versus a net loss of ₹455.87 lakhs in Q1 FY24 and ₹1,060.29 lakhs in Q4 FY24.

• Basic and diluted EPS for Q1 FY25 were (₹0.39) and (₹0.37), respectively.

Outlook and guidance

• The company is actively working to resolve compliance and transparency issues related to MSME creditor identification and payment timelines.